Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body. The company announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated. Quantum BioPharma reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food…